Amyloid pathology
AssessTechniques
Abnormal amyloid protein buildup associated with Alzheimer’s disease.
Why it's here
Placed in Assess: 1 article(s) of evidence from 1 source(s), led by regulatory news, with 0 in the last 30 days. Confidence 24%. Low accumulated evidence, so it defaults conservatively pending more signal.
Evidence (1)
- 7Hacker News·8/24/2026regulationFDA clears blood test to help evaluate Alzheimer’s disease
The U.S. Food and Drug Administration has cleared a blood test intended to aid in the evaluation of Alzheimer’s disease. The test is designed to help clinicians assess whether patients have amyloid pathology associated with the condition, adding a less invasive option to the diagnostic workflow.